AUTHOR=Ma Jun , Hu Binbin , Pan Jiayao , Liu Lunfei 

TITLE=A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1651568

DOI=10.3389/fimmu.2025.1651568

ISSN=1664-3224

ABSTRACT=BackgroundPsoriasis and hidradenitis suppurativa are chronic inflammatory skin diseases with common pathogenesis, such as the involvement of IL-17A, which also plays an essential role in the development and metastasis of colorectal cancer. Xeligekimab, a novel IL-17A inhibitor, offers a targeted therapeutic approach for these conditions.Case presentationA 43-year-old male presented with a 12-year history of plaque psoriasis and hidradenitis suppurativa. Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. His comorbidities include chronic hepatitis B managed with 10-year antiviral therapy and metastatic colorectal cancer treated with synchronous resection of liver metastases during primary tumor surgery 6 years ago (no recurrence).ResultsAfter 28 weeks of xeligekimab treatment, the patient experienced significant improvement in symptoms and skin lesions. The evaluation indicators demonstrated a sustained decline: PASI decreased from 51 to 0.8, BSA from 87% to 6%, DLQI from 20 to 1, and Hurley staging improved to Grade I. During follow-up, imaging and tumor marker testing revealed no signs of tumor and hepatitis B progression.ConclusionXeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations.